NCT00822432
- Conditions
- Burkitt Lymphoma, Central Nervous System Neoplasms, DNA Virus Infections, +24 more
- Locations
-
- Pitié-Salpêtrière Hospital Paris, France
- University Hospital Centre of Tours Tours, France
Clinical trial condition
Burkitt Lymphoma
Explore clinical trials studying Burkitt Lymphoma. Study availability and eligibility vary by location and protocol.
58 public trials
23 recruiting studies
Burkitt Lymphoma trial results
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), +136 more
- Locations
-
- Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States
Completed
Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas
NCT00001237
- Conditions
- Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +17 more
- Locations
-
- National Cancer Institute (NCI) Bethesda, Maryland, United States
Active, Not Recruiting
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
NCT04739813
- Conditions
- Burkitt Lymphoma, DNA Virus Infections, Diffuse Large B-cell Lymphoma, +17 more
- Locations
-
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
Active, Not Recruiting
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
NCT03674411
- Conditions
- Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Anemia, +48 more
- Locations
-
- Masonic Cancer Center at University of Minnesota Minneapolis, Minnesota, United States
Active, Not Recruiting
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
NCT05565417
- Conditions
- Breast Diseases, Breast Neoplasms, Bronchial Neoplasms, +58 more
- Locations
-
- Site 9618 Tucson, Arizona, United States
- Site 5000 Denver, Colorado, United States
- Site 4100 Orlando, Florida, United States
- Site 4060 Sarasota, Florida, United States
Active, Not Recruiting
Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies
NCT05270057
- Conditions
- B-cell Lymphoma, Burkitt Lymphoma, DNA Virus Infections, +15 more
- Locations
-
- University of Texas Southwestern Dallas, Texas, United States
- University of Wisconsin School of Medicine and Public Health Madison, Wisconsin, United States
- Froedtert Hospital & the Medical College of Wisconsin Milwaukee, Wisconsin, United States
Active, Not Recruiting
Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
NCT05263583
- Conditions
- Burkitt Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, +24 more
- Locations
-
- Beijing Cancer Hospital Beijing, China
- Sun Yat-sen University Cancer Center Guangzhou, China
- Henan Cancer Hospital Henan, China
- Shanghai East Hospital Pudong, China